Key facts
- Circulate (Clinics/Outpatient Services)’s last known valuation is $25.0M (Jan 2026).
- It has raised $16.0M; the latest was Seed Round ($16.0M) in Jan 2026.
- Notable investors include Khosla Ventures, Scrum Ventures, CSC UpShot Ventures, Seaside Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Circulate (Clinics/Outpatient Services)
- ·The full record, as it builds
Funding rounds
No funding rounds for Circulate (Clinics/Outpatient Services) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Circulate (Clinics/Outpatient Services)
Provider of therapeutic plasma exchange (TPE) services intended to address age-related diseases and autoimmune conditions. The company offers an evidence-based treatment that removes toxic, inflammatory, disease-causing, and age-accelerating substances from the bloodstream, and removing damaged DNA, senescent cells, and oxidative stress from your bloodstream can decelerate your aging pathways, enabling patients and health tech companies to help you live disease-free and longer.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2021
- Employees
- 17
- Website
- circulate.health/
- Ownership
- Privately Held (backing)
Circulate (Clinics/Outpatient Services) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Circulate (Clinics/Outpatient Services) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Circulate (Clinics/Outpatient Services) in its N-PORT filings yet. We sweep new filings monthly.